



## 2026 Scholars Program

### Program Description:

The Multiple Myeloma Research Foundation (MMRF) seeks proposals for the MMRF 2026 Scholars Program. The goal of this initiative is to attract and fund exceptional investigators while broadening participation among researchers whose communities, programs, and resources perspectives better reflect the demographic diversity of the real-world multiple myeloma patient population.

Applicants for the MMRF Scholars program must hold a Ph.D., M.D. or equivalent degree(s) - or are planning to defend their PhD within 12 months of the application date - and may not hold a title higher than assistant professor or equivalent at a US institution at the time of the award. Applicants must propose a clinical, translational, or basic science project relevant to the field of multiple myeloma. The Scholar program will provide up to \$400,000 of financial support over four (4) years (\$100,000/year) to successful applicants.

**Black/African American applicants with a strong interest in the multiple myeloma patient population are strongly encouraged to apply.**

### Key Dates:

- **04/06/2026 - Request for Applications (RFA) issued**
- **06/30/2026 - Deadline for Submission of Applications**
- **08/14/2026 - Applicant notification**

### Background:

Multiple myeloma is a plasma cell malignancy which is currently not curable but is a treatable disease. In the United States alone, approximately 36,000 new cases will be diagnosed this year and nearly 12,000 people will die from this disease. However, the prevalence of myeloma and reported clinical outcomes is not equal across all racial groups.

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to accelerate a cure for each and every multiple myeloma patient, with a strategic objective of driving innovation that accelerates the development of next-generation treatments to extend the lives of myeloma patients and ultimately lead to a cure. The MMRF is the world's number one private funding source for basic, translational, and clinical research in multiple myeloma, and has provided over **\$500,000,000 in financial support for more than 400 research grants and initiatives at over 140 research institutions worldwide**. As part of its continuing mission to accelerate a cure for multiple myeloma, the MMRF is committed to providing new research funding opportunities.

Significant advances in our understanding of the pathophysiology, molecular biology, and immunology of multiple myeloma and precursor conditions (Monoclonal Gammopathy of Undetermined Significance -



MGUS and Smoldering Multiple Myeloma - SMM) have identified molecular and cellular events associated with disease development and progression. These findings have led to improved understanding of disease risk and the development of new therapies for the treatment of multiple myeloma. However, to fully leverage the current armamentarium of therapeutic options and maximize clinical benefit, we still need to understand how to best optimize therapy and the sequence of therapies in the context of disease biology to tailor treatment for the individual patient.

Most myeloma patients will relapse on therapy, and consequently, undergo more aggressive therapy with the likelihood of shortened duration of clinical response. Therefore, there continues to be a need for new, novel therapies and drug combinations targeting the mechanisms that drive disease biology and drug resistance. This requires researchers to further dissect the molecular and cellular basis of disease development and progression, response to therapy, mechanisms of drug relapse, and to develop new tools and technologies to monitor for and intercept these events.

Multiple myeloma and its precursor conditions disproportionately affect the Black population relative to other racial groups. There is a 3x-higher incidence of active myeloma and a 4x-higher incidence of MGUS in the Black population compared with the White population, and the onset of disease occurs approximately 10 years earlier for Black individuals. Although there is evidence of genetic, immunologic, and environmental factors to explain these differences, the underlying molecular and cellular mechanisms are not fully understood.

This disproportionate impact is compounded by the underrepresentation of Black/African American researchers and physicians within the multiple myeloma medical community, which has significant implications for myeloma patients of Black/African descent. Black researchers and clinicians are significantly underrepresented in hematology-oncology, comprising less than 4 percent of oncology fellows and only 3 percent of medical oncologists in the United States. Shared identity between a patient and their physician has been identified as an important factor in reducing health disparities, improving participation in clinical trials, and improving patient health and treatment outcomes, particularly among minority populations.<sup>1</sup> Specific efforts will be needed to help increase the number of such researchers to directly address the under-representation in multiple myeloma and related fields. This Scholars award program is one part of an effort to improve the connection to patients disproportionately impacted by multiple myeloma.

The MMRF is currently seeking applications for the 2026 Scholars Program. Applicants should propose a clinical or laboratory project relevant to the field of multiple myeloma. All applicants must have a mentor (associate professor or higher) with established research in multiple myeloma or related fields such as genomics, cancer immunology, or bioinformatics, who will provide a research environment and guidance on study conduct and career development.

---

<sup>1</sup> Montano-Campos JF, Hahn EE, Haupt EC, Radich J, Bansal A. Oncologist-Patient Concordance and Treatment Adherence in Chronic Myeloid Leukemia. *JAMA Netw Open*. 2025;8(4):e258039. doi:10.1001/jamanetworkopen.2025.8039

**Past Award Recipients**

		
<p>2023 Award Recipient Edén Biltibo, MD Vanderbilt University Medical Center</p>	<p>2023 Award Recipient Joselle Cook, MBBS Mayo Clinic, Rochester</p>	<p>2024 Award Recipient Camille Edwards, MBBS Dana Farber Cancer Institute</p>

**Eligibility:**

Applications for the MMRF 2026 Scholars Program are requested from clinical and/or laboratory investigators at academic, not-for-profit, institutions in the United States. Researchers who either hold a Ph.D., M.D. or equivalent degree(s), or are planning to defend their PhD within 12 months of the application date are invited to apply. The Multiple Myeloma Research Foundation will not deny the benefits described in the request to individuals based on race, ethnicity, gender, sex, sexual orientation, age, religion, national origin, or other protected status under federal or state law.

The following conditions must be met by all applicants:

- **Applicant proposal must be a clinical, translational, or basic science investigation relevant to the field of multiple myeloma.** The proposal is not required to have a specific diversity, equity, and inclusion focus. As with other MMRF supported research, a diversity plan for appropriate patient population representation in clinical or laboratory research is required.
- Applicants must have a research mentor in multiple myeloma or related field who will provide a suitable research environment, guidance on study conduct and career development.
- The MMRF Scholars program is intended for early career scientists and clinicians. Applicants must have obtained their highest degree within 10 years of the application date.
- Applicants and their research must be based at an academic, not-for-profit institution in the United States.
- Applicants may not hold a position higher than Assistant Professor.

**Sponsor/Mentor Requirement:** Sponsor/mentor must be a faculty member at the host institution with independent extramural funding and established clinical expertise in multiple myeloma and/or scientific



expertise in biology relevant to multiple myeloma. The sponsor/mentor will provide a letter of support describing the applicant's qualifications, merit and relevance of project, and training environment.

Proposals must be a clinical, translational, or basic science project relevant to the field of multiple myeloma. The sponsor laboratory and host institution should have the resources available to conduct the majority of the proposed work. Space will be provided in the application to describe any additional resources such as core facilities, tissue banks, or data that may enhance or facilitate the project. The MMRF will work with the awardee to provide such additional, necessary resources where applicable.

**Program Structure:** The MMRF Scholars Program will provide financial support for salary and direct costs for laboratory research for up to four (4) years. The MMRF will work with the awardee to identify and build key collaborations and access key technologies and other resources for advancement of the proposed project.

For clinicians in an American College of Graduate Medical Education-certified Hematology/Oncology Fellowship program, research time is protected in accordance with American Board of Internal Medicine Guidelines for the Research Pathway (<https://www.abim.org/certification/policies/research-pathway/policies-requirements.aspx>). When the awardee transitions to a faculty-track position, the host institution must agree to protect a minimum of 75% of the awardee's time for research.

The MMRF will support the Scholar with the following external mentoring functions and resources:

- The MMRF Scholars Mentor Committee, consisting of clinicians and researchers in the field, will meet with the awardee on a biannual basis to review progress and provide guidance on both project conduct and career development.
- The MMRF scientific and clinical leadership will work with the awardee to find collaborators and contractors for resources and technologies that will enhance project conduct.
- The MMRF will invite the awardee to participate in MMRF-sponsored meetings, including roundtables, conferences, as well as patient-facing activities such as patient summits and seminars.
- The MMRF will reimburse travel expenses (travel, accommodations, meals) to the American Society of Hematology Annual Meeting and the International Myeloma Workshop during the years funded by the Scholars Program.

**Funding:** The funding period is four (4) years. The MMRF will provide \$100,000 annually. Up to 75% of the funding may be used for salary support for the awardee. Allowable costs include laboratory direct costs, computer hardware and software, and publication costs. Salary support for the mentor or laboratory personnel such as technicians are not allowed. Funding will be completed at the end of four years or when the Scholar transitions to Associate Professor or leaves academia, whichever comes first.

**Process:**

All applications are due **on June 30th, 2026 at 11:59 PM EST** and **must** be submitted via email to [grants@themmrf.org](mailto:grants@themmrf.org). No paper applications will be accepted.



Scholar applications are reviewed by external scientists who have the appropriate area of scientific expertise. Scientific ratings use the current National Institutes of Health (NIH) scoring system of 1-9 with 1 demonstrating the highest scientific merit and 9 being the lowest. Each proposal will be evaluated and scored by at least two independent reviewers with appropriate subject matter expertise and the reviewer scores will be averaged for a final score. The reviewers are instructed to weigh research that appears promising with the previous accomplishments of the applicant, the probability of meaningful results from the proposed research, and the likely contributions of the research to advance the myeloma research community's knowledge of disease biology, diagnosis, and treatment. In addition, support by a research mentor or sponsor must be adequately demonstrated. Furthermore, the objectives of the proposal must be reasonable to be performed over the course of the four-year grant period. MMRF will notify all applicants of the outcome of their grant application on **August 14th, 2026**.

**Funds Available:**

Investigators may request up to \$100,000 total costs per year for a four (4) year period (total award is \$400,000)

**(a) Permissible Costs.**

- (i) Salary for the Research Scholar with the following restrictions:
  - (1) the percent salary (with fringe benefits) cannot exceed the percent effort set forth in the Approved Budget.
  - (2) the salary request (with fringe benefits) cannot exceed seventy-five percent (**75%**) of the total grant request.
- (ii) Expendable supplies.
- (iii) Other expenses directly related to the conduct of Grant Research.
- (iv) Indirect operating costs incurred by the Sponsoring Institution during the Grant Term in an amount **not to exceed ten percent (10%)** of the total costs. Indirect operating costs are to be included in the total award amount, and not in addition to it.
- (v) Notwithstanding the foregoing, in no event shall the base salary exceed the annual Federal capitation imposed by the National Institutes of Health.

**(b) Impermissible Costs.**

- (i) Construction, alteration, maintenance or rental of buildings or building space.



- (ii) Office equipment and furniture.
- (iii) Dues for membership in scientific societies.
- (iv) Office supplies including, but not limited to, mail/postage costs, copying costs, telephone, fax, internet access or other similar costs.
- (v) Tuition, books and journals.
- (vi) Significant Equipment costs.
- (vii) Any other costs not specifically listed in Permissible Cost.

The funds awarded shall be used solely for the purposes specified in the application submitted to the MMRF as executed by the Scholar and institution in compliance with the budget annexed to the application.

In addition to the base award funds, the MMRF will reimburse the Scholar for expenses associated with attendance to the American Society of Hematology Annual Meeting up to \$1,000 and the International Myeloma Workshop (up to \$1,000 when this meeting is in North America, and up to \$2,000 for when this meeting is at an international location) for the duration of the award. The Scholar will be expected to participate in Research and Clinical meetings organized by MMRF that are coincident with the American Society of Hematology Annual Meeting and the International Myeloma Workshop.

**Application Information:**

All applications must be electronically submitted via email to [grants@themmrf.org](mailto:grants@themmrf.org). All application instructions are provided below and will also be available on this site.

**For inquiries about the Scholars Program contact: [grants@themmrf.org](mailto:grants@themmrf.org).**



**Multiple Myeloma Research Foundation  
2026 Scholars Program  
Application Instructions**

**A. General Requirements**

**a. Required Format:** Applications must be in English using single-spaced text, half-inch margins, using either Arial or Times New Roman 11- or 12-point font. Page limitations must be observed for each section as described below.

**b. Good Standing:** Applications will only be accepted from research investigators who are currently in good standing with the MMRF. An applicant will automatically be considered to be in good standing unless they have failed to provide progress reports on prior MMRF-funded grants.

**Note:** Sections B – E must be completed in the template titled “Prerequisite Applicant Information” which is provided in Exhibit B of this document. Please download the template, complete each section and save the document, and then submit it as a single PDF file.

**B. Abstract**

This Section should contain the following:

- 1) A General Audience Abstract: briefly describe your proposed project in 100 words or less using non-technical language (i.e., at a level that an eighth grader would understand)
- 2) A Technical Abstract: briefly describe your proposed project in 100 words or less using technical language.

**C. Biographical Sketch**

This Section should contain the NIH format biographical sketches of the Principal Investigator and Mentor.

**D. Budget**

Please provide a detailed budget and budget justification fully outlining specific needs for Scholar and itemized supplies by category. Please see the definition of Permissible and Impermissible Cost in the above section on *Funds Available*.

All budget items should be explained under *Budget Justification*.

**E. Other Research Support**



Other support is defined as any specific funds or resources, whether governmental, non-governmental or institutional, available to the Principal Investigator (and the other key personnel named in the application) in direct support of their research endeavors. This should include active support and pending support.

Information regarding active or pending sources of support available to the Principal Investigator (and other key personnel named in the application), whether related to this application or not, is an important part of the review and award process and must be included.

**Note:** Sections F - G should be completed in the template titled “Application Template” which is provided in Exhibit C of this document. Complete each section in the template and submit it as a single PDF file.

## **F. Project Description**

Limited to **5 pages**, but excluding necessary supporting materials such as references, figures, and tables (*see Section G regarding submission of supporting materials*). The project description should be presented in the following sequence:

- i** Specific Aims (approximately 0.5 pages)
- ii** Scientific Background and Clinical Significance of Proposed Studies (approximately 1.0 pages)
- iii** Previous Work or Preliminary Data (approximately 1.5 pages)
- iv** Methods, Model Systems and Assays (approximately 1.0 pages)
- v** Plans for Clinical Application of Data (if applicable; approximately 0.5 pages)
- vi** Resources and Environment including support from research mentor/sponsor (approximately 0.5 page)

If part of the application, Clinical Research protocols must be submitted as materials in the Appendix. Include IRB/Ethical Committee approval/compliance number or indicate pending and an anticipated approval date.

## **G. Supporting Materials (References, Figures and Tables)**

Any referenced publications in the Project Description, Figures, and Tables should be submitted as materials in the Appendix, and will not count against the five (5) page limit in Section F (Project Description).

**Note:** There is no template provided for Sections H – N. These documents need to be submitted as separate PDF files. Please see each section for any specific instructions or notes.

## **H. Patient Population Impact Plan (1 page)**

For clinical and translational projects that involve human subjects or samples from human subjects, applicants must provide a description of intended ethnic and racial populations appropriate for the project and plans for recruitment of these populations. Applicants may describe specific programs, resources, and collaborations at their institution that will support this effort. This will not count against



the five (5) page limit in Section F of the Project Description.

**I. Request for Resource Support (Optional)**

The MMRF may be able to provide access to *non-essential* external research resources and expertise through its network of collaborator institutions and investigators. Applicants who may benefit from access to novel or advanced research technologies and platforms, or expertise, to enhance the conduct of the project described in their application may request assistance from the MMRF to identify the required resources or expertise. Applicants requesting Resource Support must provide a brief description of their expected external technical or expertise needs and how they would add to the conduct (0.5 pages).

**J. Letter of Support**

Candidates must include a letter of support with their application. This letter must be from a senior faculty Mentor who is active in the myeloma field, commenting on the qualifications and potential of the applicant and stating that they are able to provide an appropriate research environment and career guidance for the candidate.

**K. Laboratory Animals Statement**

For projects which involve laboratory animals, the Institutional Animal Care and Use Committee (IACUC) Approval Date and Animal Welfare Assurance number must be given. Non-US applicants must submit approval documentation from their Animal Ethics Committee.

**Note:** If an applicant has Laboratory Animal documentation to submit then this documentation must be submitted as a separate PDF file.

**L. Biohazards Statement**

An institutional statement and assurances regarding potential biohazards and safeguards must be included.

**Note:** The Department of Environmental Health and Safety (or equivalent office) at most institutes and universities can provide the applicant with a letter stating that the laboratory and/or the applicant is in compliance with applicable laws. This is the document that should be submitted.

**M. Relevant Publications**

A set of the applicant's publication reprints which are relevant to the proposed project can be included. Please be aware that any password protection feature **must** be removed. Many articles when downloaded from journal sites contain password protection to prevent modifications of the document. **Please note:** if the password protection is not removed, reviewers will have difficulty in downloading your application. Applicants will be limited to five (5) publication reprints. Applications with more than five (5) publications will not be accepted. Submitting numerous large files adds to the download time of your application and can create complications when submitting the application materials via email.



**Note:** Applicants may either include all publications in one document as a Publication Appendix or submit each publication as a separate Appendix to the application. Include in the name of the document(s) or Appendix(s) the following: 1) Applicant's last name and 2) description of the document or appendix. For example: Smith Publication Appendix. PDF (one document with all publications) or Smith Paper on Mouse Model X. PDF and Smith Paper on Myeloma Drug Y. PDF, etc.

#### **N. Signatures:**

The signature page is provided as a printable document and is the last step before submitting the application. Applicants should print the signature page, sign (applicant) and then have the appropriate institutional representatives sign the document; e.g., the Institute Signing Official and Finance Officials. **Please check with your institute's Office of Sponsored Programs, or equivalent, to ensure you are obtaining the appropriate signatures.** Once signed, the document needs to be scanned, converted to a PDF and submitted with the grant application.

**Note:** This signature page needs to be submitted as a PDF file. See Section O: Complete and Submit the Application for instructions.

#### **O. Complete and Submit the Application:**

All applicants must submit a complete application via email by sending the package of application materials to [grants@themmrf.org](mailto:grants@themmrf.org).

**NOTE: PAPER APPLICATIONS WILL NOT BE ACCEPTED. ALL APPLICATIONS MUST BE ELECTRONICALLY SUBMITTED BY 11:59 PM EST ON JUNE 30<sup>th</sup>, 2026. APPLICATIONS RECEIVED AFTER JUNE 30<sup>th</sup>, 2026 WILL NOT BE CONSIDERED.**

#### **P. Publicity, Exhibits and Publication.**

- 1. Announcement and MMRF Publication of Award.** MMRF reserves the right to publicly announce that it has provided Sponsoring Institution and Principal Investigator a grant award and the amount of the grant. MMRF will ask for an abstract of the Grant Research to be conducted. The Sponsoring Institution shall obtain any internal approvals necessary to grant MMRF the right to use of its name, logo, and likeness prior to execution of this Grant Agreement. Sponsoring Institution shall not unreasonably withhold such approval.
- 2. Program Marketing.** The Sponsoring Institution and Principal Investigator hereby, as a condition to receiving Grant Funds, agree to participate in publicity activities, including, but not limited to, being interviewed for MMRF newsletters, press releases, and video as requested by the MMRF as well as acknowledge the grant award in Sponsoring Institution's donor marketing materials.
- 3. Prior Notification of Promotion, Presentation or Exhibition.** MMRF shall receive written notice from Principal Investigator at least thirty (30) days prior to any publication, exhibition or presentation relating to Grant Information (which notification shall include



a copy of the materials intended for release, as well as the details of the information to be disclosed and the time, place and manner of such disclosure).

4. **Credits.** All published works, including, but not limited to, on-line publications, exhibitions, presentations, marketing materials or other disclosures of Grant Information or summaries thereof by Sponsoring Institution or Principal Investigator must display the designation, "Supported by a Research Grant from the Multiple Myeloma Research Foundation (MMRF)."
5. **MMRF Publication of Results.** MMRF shall have the right to include published Grant Information results on its website or in other MMRF materials.
6. **Data Sharing.** MMRF is hereby granted an irrevocable, worldwide, non-exclusive, royalty free, sublicensable license to the de-identified (as defined by HIPAA) data and results generated in the performance of Grant Research to include in the MMRF data repository. Sponsoring Institution and Principal Investigator shall provide de-identified (as defined by HIPAA) data, Experimentals, and results of the Grant Research to MMRF in digital format for incorporation into data repository along with the Final Report. MMRF may incorporate into data repository de-identified (as defined by HIPAA) data, Experimentals, and results of the Grant Research received with the Final Report at the earlier of eighteen (18) months from receipt, or upon publication of the Grant Research by Sponsoring Institution or Principal Investigator. Sponsoring Institution and Principal Investigator agree that once MMRF has incorporated such de-identified (as defined by HIPAA) data, Experimentals, and results into the data repository, MMRF will have the unrestricted right to use, distribute, share, and publish the de-identified (as defined by HIPAA) data, Experimentals, and results.



## EXHIBIT A

### Patent, Intellectual Property and Technology Transfer Policy of the Multiple Myeloma Research Foundation, Inc.

1. **Disclosure and Assignment of Invention(s) by the Principal Investigator; Report to MMRF.**
  - (a) **Disclosure and Assignment of Invention(s) by Principal Investigator.** The Sponsoring Institution shall require the Principal Investigator and all other persons engaged in the Grant Research to promptly:
    - (i) disclose all Inventions to the Office of Technology (or the equivalent) of the Sponsoring Institution;
    - (ii) assign to the Sponsoring Institution all of their rights, title, and interest in and to all Inventions which are conceived, discovered, or reduced to practice by such person during the course of the Grant Research at the Sponsoring Institution;
    - (iii) require all such persons to cooperate fully with the Sponsoring Institution in pursuing legal protection for any Inventions or improvements thereto, including but not limited to providing assistance in filing and presenting any patent applications for or copyrights on such Inventions or improvements.
  - (b) **Reporting to MMRF.** Institution and/or Principal Investigator shall report any invention or lack thereof to MMRF on an annual basis on or about April 30<sup>th</sup>. Notwithstanding the foregoing, all Inventions shall be reported to MMRF in writing within three (3) months after their disclosure to the Sponsoring Institution.
2. **Sponsoring Institution's Duty to Decide on Protection of Invention and Notify MMRF.** Sponsoring Institution shall determine whether it will seek patent or other statutory protection for each Invention promptly after such Invention is disclosed to the Sponsoring Institution, and it shall promptly notify MMRF of its decision. Upon MMRF's request, Sponsoring Institution shall notify MMRF when documentation relating to the filing or assertion of rights has been published and are publicly available.
3. **Licensing of Invention by Sponsoring Institution.**
  - (a) **Notice to MMRF of Possible Revenue-Generating Agreement.** If the Sponsoring Institution contemplates entering into a license, assignment, or other revenue-generating agreement relating to the Invention, the Sponsoring Institution shall give MMRF written notice thereof prior to execution.
  - (b) **Requirements for Such Agreement.** Any agreements referred to in Section 3(a) of this Exhibit D relating to Inventions shall be entered into by the Sponsoring



Institution and/or the Principal Investigator on an arm's-length basis with the licensee, assignee, or transferee as the case may be.

4. **Participation in Income.** MMRF shall have the right to participate in the income derived from any Invention, unless MMRF explicitly waives such right in writing, and the parties hereby agree that no provision of the Agreement shall constitute such a waiver. This right to participate shall include the sharing of licensing fees and royalties and any other consideration derived from an Invention by Sponsoring Institution and/or Principal Investigator at a rate of twenty percent (20%) of net income up to a cap of five (5) times the grant amount funded by MMRF. MMRF's participation in income hereunder shall be paid on a calendar yearly basis and shall be accompanied by copies of all invoices sent by Sponsoring Institution to its licensees, assignees and/or transferees as the case may be. MMRF shall have the right to audit Sponsoring Institution's books with advance written notice and records no more frequently than one time per year to verify the payments hereunder, with the understanding that access to such information shall be limited by any obligations of confidentiality that the Sponsoring Institution has to its licensees, assignees or transferees.

**EXHIBIT B**  
**Prerequisite Applicant Information**

Applicant Name (Last, First, Middle): \_\_\_\_\_

---

**Abstracts**

---

***General Audience Abstract:*** Briefly describe your proposed project in 100 words or less. Be sure to use language that can be easily understood by a general audience.

***Technical Abstract:*** Briefly describe your proposed project in 100 words or less.

Applicant Name (Last, First, Middle):

---

**BIOGRAPHICAL SKETCH**

Provide the following information for all key personnel.

Follow the sample format for each person found in **Biosketch Sample**. **DO NOT EXCEED TWO (2) PAGES.**

---

NAME	POSITION TITLE
------	----------------

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.*)

INSTITUTION AND LOCATION <i>(if applicable)</i>	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY

A. Positions and Honors.

B. Selected peer-reviewed publications (in chronological order).

Applicant Name (Last, First, Middle):

<b>DETAILED BUDGET FOR THE YEAR***</b>						FROM	THROUGH
PERSONNEL			% EFFORT ON PROJ.	INST. BASE SALARY	DOLLAR AMOUNT REQUESTED <i>(omit cents)</i>		
NAME	ROLE ON PROJECT				SALARY REQUESTED	FRINGE BENEFITS	TOTAL
<b>SUBTOTALS</b> →							
EQUIPMENT <i>(Itemize)</i>							
SUPPLIES <i>(Itemize by category)</i>							
TRAVEL <i>(not to exceed \$1500)</i>							
OTHER EXPENSES <i>(Itemize by category)</i>							
<b>TOTAL DIRECT COSTS (TDC) FOR INITIAL BUDGET PERIOD</b>					<b>\$</b>		
<b>TOTAL FACILITIES AND ADMINISTRATIVE (INDIRECT) COSTS FOR INITIAL BUDGET PERIOD</b> <b>(MAXIMUM 10% of TDC)</b>					<b>\$</b>		
<b>TOTAL COSTS FOR INITIAL BUDGET PERIOD</b>					<b>\$</b>		

\*\*\* Please refer to Policies & Procedures regarding permissible and non-permissible costs

Applicant Name (Last, First, Middle):

**BUDGET JUSTIFICATION.** Follow the budget justification instructions. **Do not exceed 2 Pages.**

**Other Research Support**

---

*List other research support available to the principal investigator (and other key personnel listed in the application).*

**EXHIBIT C**  
**Application Template**

Applicant Name (Last, First, Middle): \_\_\_\_\_

---

**PROJECT DESCRIPTION (Not to Exceed 5 Pages)**

---

- (A) Specific Aims (0.5 pages)**
- (B) Scientific Background and Clinical Significance of Proposed Studies (1.0 pages)**
- (C) Previous Work/Preliminary Data (1.5 pages)**
- (D) Methods, Model Systems and Assays Proposed (1.0 pages)**
- (E) Plans for Clinical Application of Data (0.5 pages)**
- (F) Resources and Environment (0.5 pages)**

Applicant Name (Last, First, Middle):

---

**Supporting Materials**

---

**References:**

**Figures:**

**Tables:**